Acuta Capital Partners, LLC Sage Therapeutics, Inc. Transaction History

Acuta Capital Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $2.05 Million - $2.92 Million	-50,945 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $3.71 Million - $5.36 Million	-67,555 Reduced 57.01%	50,945 $2.89 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $9.7 Million - $13.3 Million	-137,300 Reduced 53.67%	118,500 $8.87 Million
Q4 2020 Feb 16, 2021	BUY	$58.41 - $89.06 $1.8 Million - $2.74 Million	30,800 Added 13.69%	255,800 $22.1 Million
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $9.25 Million - $14.1 Million	225,000 New	225,000 $13.8 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $333M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.